Coming December: ASH publishes its late-breaking abstracts. We’ll add the organizations presenting them.

Bristol Myers Squibb at ASH 2026

Dec 12–15, 2026 New Orleans, LA ~30k attendees Website

Bristol Myers Squibb brings 14 presentations to ASH 2026 in New Orleans, and exhibits at Booth 1313. Bristol Myers Squibb supports educational symposia on myeloma CAR T-cell therapy, myelofibrosis and lymphoma, and hosts theater sessions on myeloma. Its research covers a BCL6 degrader and a platform for biomarker discovery.

OrganizationASH 2026 Attendance
Large pharma
Global biopharmaceutical company with hematology medicines in myeloma, lymphoma, leukemia and anemia, including CAR T-cell therapies.
Booth
Exhibiting at Booth 1313
Sat, Dec 1211:00am–5:00pmSun, Dec 1310:00am–5:00pmMon, Dec 1410:00am–2:00pm
Symposium
Fri Dec 11
7:00am–10:00am
Next in Line for Relapsed/Refractory Myeloma: Sequencing Strategies With T-Cell Engagers, Next-Generation CAR-T, and Innovative MOAs
Sequencing relapsed myeloma treatments as next-generation CAR-T, multi-target T-cell engagers, and new drug classes arrive, plus managing their toxicity.
Symposium hosted by PeerView Institute for Medical Education
Myeloma · New drugs
Symposium
Fri Dec 11
11:00am–2:00pm
A Case-Based Exploration of CAR T-Cell Therapy in Multiple Myeloma – Where We Are, Where We’re Going
Real patient cases showing how experts use approved and investigational CAR-T therapies in multiple myeloma now, and where the treatment is heading.
Myeloma · Cell & gene
Symposium
Fri Dec 11
11:00am–2:00pm
CAR T-Cell Agent Integration in Lymphoma: A Masterclass for Real-World Implementation
CAR-T for relapsed B-cell lymphomas, from patient selection and referral to managing immune and nerve toxicities, survivorship, and off-the-shelf products.
Symposium hosted by Decera Clinical Education
Lymphoma · Cell & gene
Symposium
Fri Dec 11
11:00am–2:00pm
The CELMoD Shift: Translating Protein Degradation Science into Practice-Changing Myeloma Care
Cereblon-modulating protein degraders for relapsed myeloma, from biology and trial data to sequencing, neutropenia management, and residual disease testing.
Myeloma · New drugs
Symposium
Fri Dec 11
3:00pm–6:00pm
A Case-Based Exploration of Current and Future Directions in Myelofibrosis – Where We Are, Where We’re Going
Real patient cases showing how experts treat myelofibrosis today, paired with reviews of current data and ongoing research on emerging therapies.
Leukemias
Symposium
Fri Dec 11
3:00pm–6:00pm
MDS in the Modern Era: Getting Ahead of the 8-Ball
Moving myelodysplastic syndrome care toward early disease-modifying drugs, with hypomethylating agents for higher-risk disease and wider transplant access.
Leukemias
Symposium
Fri Dec 11
7:00pm–10:00pm
Addressing Community Oncologists’ Questions About Novel Therapies in Non-Hodgkin Lymphoma – What Clinicians Want To Know
Answers to community oncologists' most pressing questions about new drugs for non-Hodgkin lymphoma, drawn from a survey and reviewed against current research.
Lymphoma

Explore the full ASH 2026 dataset

Get in-depth attendee and institution profiles and research, to plan your meetings in New Orleans. Leave your work email and we’ll be in touch.

Privacy

Download the full ASH 2026 CSV

Leave your work email and we’ll be in touch. The CSV adds attendee names, roles and contact details to the company and session data shown here.

Privacy

Find decision makers at Bristol Myers Squibb

Tell us what you sell and we’ll find the people at Bristol Myers Squibb most likely to buy it.

  • Who to contact
  • Their contact info
  • What to say
  • Free, no sign-up

Not affiliated with or endorsed by the American Society of Hematology (ASH). Submit a correction